Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ZIOPHARM Oncology Inc. : ZIOPHARM Oncology to Present at the 38th Annual Deutsche Bank Health Care Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/22/2013 | 01:48pm CEST

BOSTON, May 22, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, will present at the 38th Annual Deutsche Bank Health Care Conference on Wednesday, May 29th, 2013 at 8:00 a.m. ET at the Westin Boston Waterfront Hotel in Boston, Massachusetts.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company's clinical programs include:

Ad-RTS-IL-12 is currently being tested in two Phase 2 studies, the first for the treatment of advanced melanoma, and the second in combination with palifosfamide for the treatment of non-resectable recurrent or metastatic breast cancer. Ad-RTS-IL-12 uses synthetic biology to enable controlled delivery of therapeutic interleukin-12 (IL-12), a protein important for enhancing the development of an immune response to cancer. In partnership with Intrexon Corporation, ZIOPHARM's DNA synthetic biology platform employs an inducible gene-delivery system that enables controlled delivery of genes that produce therapeutic proteins to treat cancer. This controlled delivery is achieved by producing IL-12 under the control of Intrexon's proprietary biological "switch" (the RheoSwitch Therapeutic System® or RTS® platform) to turn on/off the therapeutic protein expression at the tumor site.

Palifosfamide (ZIO-201) is a potent, bi-functional DNA alkylating agent that has activity in multiple tumors by evading typical resistance pathways. Palifosfamide is in the same class as bendamustine, cyclophosphamide, and ifosfamide. It is currently being studied in an adaptive Phase 3 study in small cell lung cancer. Enrollment in this study was suspended with 188 subjects randomized, and being followed for overall survival. Data is expected in the first half of 2014.

Indibulin (ZIO-301) is a novel, tubulin binding agent that is expected to have several potential benefits, including oral dosing, application in multi-drug resistant tumors, no neuropathy and a tolerable toxicity profile. It is currently being studied in a Phase 1/2 trial in metastatic breast cancer.

Darinaparsin (ZIO-101) is a novel mitochondrial-and hedgehog-targeted agent (organic arsenic) currently in ongoing studies with Solasia Pharma K.K.

ZIOPHARM's operations are located in Boston, MA. Further information about ZIOPHARM may be found at www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains certain forward-looking information about ZIOPHARM Oncology, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s)," "will," "may," "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our ability to successfully develop and commercialize our therapeutic products; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and future performance. All of such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to: whether palifosfamide, Ad-RTS-IL-12, darinaparsin, indibulin, or any of our other therapeutic products will advance further in the clinical trials process and whether and when, if at all, they will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies and for which indications; whether palifosfamide, Ad-RTS-IL-12, darinaparsin, indibulin, and our other therapeutic products will be successfully marketed if approved; whether any of our other therapeutic product discovery and development efforts will be successful; our ability to achieve the results contemplated by our collaboration agreements; the strength and enforceability of our intellectual property rights; competition from other pharmaceutical and biotechnology companies; the development of, and our ability to take advantage of, the market for our therapeutic products; our ability to raise additional capital to fund our operations on terms acceptable to us; general economic conditions; and the other risk factors contained in our periodic and interim SEC reports filed from time to time with the Securities and Exchange Commission, including but not limited to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2013. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof, and we do not undertake any obligation to revise and disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

CONTACT: For ZIOPHARM:

         Jason A. Amello

         ZIOPHARM Oncology, Inc.

         617-778-6730

         [email protected]

         

         Media Contacts:

         David Schull or Lena Evans

         Russo Partners, LLC

         858-717-2310

         212-845-4262

         [email protected]

         [email protected]
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY INC.
05/17 ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent..
05/12 ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Other Events
05/12 ZIOPHARM ONCOLOGY INC : Other Events, Financial Statements and Exhibits (form 8-..
05/12 ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Comm..
05/02 ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Other Events
05/02 ZIOPHARM ONCOLOGY INC : Other Events, Financial Statements and Exhibits (form 8-..
05/02 ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cel..
05/01 ZIOPHARM ONCOLOGY : reports 1Q loss
05/01 ZIOPHARM ONCOLOGY, INC. (NASDAQ : ZIOP) Files An 8-K Results of Operations and F..
05/01 ZIOPHARM ONCOLOGY INC : Results of Operations and Financial Condition, Financial..
More news
Sector news : Bio Therapeutic Drugs
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/12 ZIOPHARM prices equity offering; shares down 11%
05/03 ZIOPHARM ONCOLOGY : Key To The CAR-T Mint
05/01 ZIOPHARM Oncology's (ZIOP) CEO Laurence Cooper on Q1 2017 Results - Earnings ..
05/01 ZIOPHARM Oncology misses by $0.03, misses on revenue
03/27 ZIOPHARM poised to advance lead gene therapy candidate into Phase 3; shares a..
Advertisement
Financials ($)
Sales 2017 6,50 M
EBIT 2017 -71,6 M
Net income 2017 -81,6 M
Finance 2017 1,00 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 151x
Capi. / Sales 2018 168x
Capitalization 983 M
More Financials
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | ZIOP | US98973P1012 | 4-Traders
Full-screen chart
Technical analysis trends ZIOPHARM ONCOLOGY...
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 14,8 $
Spread / Average Target 113%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer & Managing Director
Murray F. Brennan Chairman
Caesar J. Belbel COO, Secretary, Chief Legal Officer & Executive VP
Kevin G. Lafond Chief Financial Officer, Treasurer, CAO & VP
Francois Lebel Chief Medical Officer, EVP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.30.84%995
AMGEN, INC.5.74%112 531
CELGENE CORPORATION1.35%90 349
GILEAD SCIENCES, INC.-10.19%84 101
REGENERON PHARMACEUTIC..25.68%48 999
ACTELION LTD24.49%30 824
More Results